Meta-Analysis of Clinical Dose–Response in a Large Drug Development Portfolio

Statistics in Biopharmaceutical Research

Volumn 6, Issue 4, 2014, Pages 302-317

  Thomas, Neal ^a   Sweeney, Kevin ^a   Somayaji, Veena ^a  

^a PFIZER INC   (United States)

Author keywords

Bayesian pharmacometric models; Dosing design; Emax

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHODIESTERASE V INHIBITOR; PLACEBO;

ALGORITHM; ARTICLE; BAYES THEOREM; CARDIOVASCULAR DISEASE; CLINICAL PHARMACOLOGY; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; EMAX MODEL; HUMAN; META ANALYSIS; METABOLIC DISORDER; OUTCOME ASSESSMENT; PREDICTIVE VALUE; SENSITIVITY ANALYSIS; SIMULATION; STATISTICAL MODEL; STUDY DESIGN; VIRUS LOAD;

EID: 84926031850     PISSN: None     EISSN: 19466315     Source Type: Journal    
DOI: 10.1080/19466315.2014.924876     Document Type: Article

References (47)

1. Bates, D., and Watts, D. (1988), Nonlinear Regression Analysis and Its Applications, New York: Wiley.
2. Berry, D., Muller, P., Grieve, A., Smith, M., Parke, T., Blazek, R., Mitchard, N., and Krams, M. (2002), “Adaptive Bayesian Designs for Dose-Ranging Trials,” in Case Studies in Bayesian Statistics V, eds. B. Carlin, A. Carriquiry, C. Gatsonis, et al., New York: Springer, pp. 99–181.
3. Bornkamp, B. (2012), “Functional Uniform Priors for Nonlinear Modeling,” Biometrics, 68, 893–901.
4. Bornkamp, B., and Ickstadt, K. (2009), “Bayesian Nonparametric Estimation of Continuous Monotone Functions With Applications to Dose–Response Analysis,” Biometrics, 65, 198–205.
5. Bornkamp, B., Bretz, F., Dette, H., and Pinheiro, J. (2011), “Response-Adaptive Dose-Finding Under Model Uncertainty,” The Annals of Applied Statistics, 5, 1611–1631.
6. Bretz, F., Hothorn, L., and Hsu, J. (2003), “Identifying Effective and/or Safe Doses by Stepwise Confidence Intervals for Ratios,” Statistics in Medicine, 22, 847–858.
7. Bretz, F., Pinheiro, J., and Branson, M. (2005), “Combining Multiple Comparisons and Modeling Techniques in Dose–Response Studes,” Biometrics, 61, 738–748.
8. Bretz, F., Dette, H., and Pinheiro, J. (2010), “Practical Considerations for Optimal Designs in Clinical Dose–Finding Studies,” Statistics in Medicine, 29, 731–742.
9. Calabrese, E., and Baldwin, L. (2001), “The Frequency of u-Shaped Dose Responses in the Toxicology Literature,” Toxicological Sciences, 62, 330–338.
10. Congressional Budget Office (2006), Research and Development in the Pharmaceutical Industry, Congressional Budget Office Study, available at http://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/76xx/doc7615/10-02-drugr-d.pdf
11. Cook, S., Gelman, A., and Rubin, D. (2006), “Validation of Software for Bayesian Models Using Posterior Quantiles,” Journal of Computational and Graphical Statistics, 15, 675–690.
12. Dette, H., Bretz, F., Pepelyshev, A., and Pinheiro, J. (2008), “Optimal Designs for Dose-Finding Studies,” Journal of the American Statistical Association, 103, 1225–1237.
13. Dette, H., Kiss, C., Bevanda, M., and Bretz, F. (2010), “Optimal Designs for the Emax, Log-Linear and Exponential Models,” Biometrika, 97, 513–518.
14. Dunnett, C. (1955), “A Multiple Comparison Procedure for Comparing Several Treatments With a Control,” Journal of the American Statistical Association, 50, 1096–1121.
15. max Model With the Truncated Data Typical of Clinical Studies? Journal of Pharmaceutical Sciences, 85, 232–239.
16. Vantage, Inc. (2010), “Pharma Industry Cutting Its R&D Cloth to More Sustainable Levels,” available at http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=217946§ionID=&isEPVantage=yes.
17. Gries, J., Munafo, A., Porchet, H., and Verotta, D. (1999), “Down-Regulation Models and Modeling of Testosterone Production Induced by Recombinant Human Choriogonadotropin,” The Journal of Pharmacology and Experimental Therapeutics, 289, 371–377.
18. Holford, N., and Sheiner, L. (1981), “Understanding the Dose–Response Relationship: Clinical Application of Pharmacokinetic-Pharmacodynamic Models,” Clinical Pharmacokinetics, 6, 429–453.
19. Hsu, J., and Berger, R. (1999), “Stepwise Confidence Intervals Without Multiplicity Adjustment for Dose–Response and Toxicity Studies,” Journal of the American Statistical Association, 94, 468–483.
20. Iliadis, A., and Macheras, P. (2006), Modeling in Biopharmaceutics, and Pharmacodynamics: Homogeneous and Heterogeneous Approaches, New York: Springer.
21. Johnson, N., and Kotz, S. (1995), Continuous Univariate Distributions (vol. 2), New York: Wiley.
22. Kahn, M., and Raftery, A. (1996), “Discharge Rates of Medicare Stroke Patients to Skilled Nursing Facilities: Bayesian Logistic Regression With Unobserved Heterogeneity,” Journal of the American Statistical Association, 91, 29–41.
23. Krishna, R. (2006), Dose Optimization in Drug Development, Boca Roton, FL: CRC Press.
24. Lunn, D., Spiegelhalter, D., Thomas, A., and Best, N. (2009), “The BUGS Project: Evolution, Critique and Future Directions” (with discussion), Statistics in Medicine, 28, 3049–3082.
25. max Model,” in Dose–Finding in Drug Development, ed. N. Ting, New York: Springer.
26. Mandema, J., Hermann, D., Wang, W., (2005), “Model-Based Development of Gemcabene, a New Lipid-Altering Agent,” The AAPS Journal, 7, E513–E522.
27. Mandema, J., Boyd, R., and DiCarlo, L. (2011), “Therapeutic Index of Anitcoagulants for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose–Response Meta-Analysis,” Clinical Pharmacology and Therapeutics, 90, 820–827.
28. McDonald, J. (2005), “Isotonic Regression,” in Encyclopedia of Biostatistics, eds. P. Armitage, T. Colton, New York: Wiley, pp. 2115–2116.
29. Meffin, P., Winkle, R., Blaschke, T., Fitzgerald, J., and Harrison, D. (1977), “Response Optimization of Drug Dosage: Antiarrythmic Studies and Tocainide,” Clinical Pharmacology and Therapeutics, 22, 42–57.
30. Nissen, S., Nicholls, S., Wolski, K., Howey, D., McErlean, E., Wang, M., Gomez, E., and Russo, J. (2007), “Effects of a Potent and Selective Ppar-α Agonist in Patients With Atherogenic Dyslipidemia or Hypercholesterolemia,” Journal of the American Medical Association, 297, 1362–1373.
31. Pfizer, Inc. (2009), “Creating the World’s Premier Biopharmaceutical Company,” available at http://www.pfizer.com/files/investors/presentations/q4earnings_january012509.pdf.
32. (2008), “Profile 2008: Pharmaceutical Industry,” available at http://www.amsa.org/AMSA/Libraries/Committee_Docs/2008Profile.sflb.ashx.
33. Posekany, A., Felsenstein, K., and Sykacek, P. (2008), “Biological Assessment of Robust Noise Models in Microarray Data Analysis,” Bioinformatics, 27, 807–814.
34. R Development Core Team (2011), R: A Language and Environment for Statistical Computing, Vienna, Austria: R Foundation for Statistical Computing.
35. Ross, G. (1990), Nonlinear Estimation, New York: Springer.
36. Ruberg, S. (1989), “Dose-Reponse Studies II. Analysis and Interpretation,” Journal of Biopharmaceutical Statistics, 5, 15–42.
37. Sheiner, L., Beal, S., and Dunne, A. (1997), “Analysis of Nonrandomly Censored Ordered Categorical Longitudinal Data From Analgesic Trials,” Journal of the American Statistical Association, 92, 1235–1244.
38. (2013), Stan: A C++ Library for Probability and Sampling, available at http://mc-stan.org/, 1.3 edition.
39. Tamhane, A., Hochberg, Y., and Dunnett, C. (1996), “Multiple Test Procedures for Dose–Finding,” Biometrics, 52, 21–37.
40. Tan, H., Gruben, D., French, J., and Thomas, N. (2011), “A Case Study of Model-Based Bayesian Dose–Response Estimation,” Statistics in Medicine, 30, 2622–2633.
41. max Model Applied to Sparse Dose–Response Designs,” Journal of Biopharmaceutical Statistics, 16, 657–677.
42. Ting, N. (2006), Dose–Finding in Drug Development, New York: Springer.
43. Tukey, J. (1977), Exploratory Data Analysis, Reading, MA: Addison-Wesley.
44. Venables, W., and Ripley, B. (2002), Modern Applied Statistics With S (4th ed.), New York: Springer.
45. Williams, D. (1971), “A Test of Differences Between Treatment Means When Several Doses are Compared With a Zero Dose,” Biometrics, 27, 103–117.
46. Winkle, R., Meffin, P., Fitzgerald, J., and Harrison, D. (1976), “Clinical Efficacy and Pharmacokinetics of a New Orally Effective Antiarrhythmic Tocainide,” Circulation, 54, 884–889.
47. Woodward, P. (2012), Bayesian Analysis Made Simple: An Excel GUI for WinBUGS, Boca Raton, FL: CRC Press.